Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|19|17|3150-3160

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.17, 2013-05, pp. : 3150-3160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel microsomal triglyceride transfer protein inhibitors

By Williams Spencer J   Best James D  

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 4, 2003-04 ,pp. : 479-488

Informa Healthcare

Access to resources Recommend Favorite

The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease

By  

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 3143-3149

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging options in the treatment of dyslipidemias: a bright future?

By Florentin Matilda   Liberopoulos Evangelos N   Mikhailidis Dimitri P   Elisaf Moses S  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 2, 2011-06 ,pp. : 247-270

Informa Healthcare

Access to resources Recommend Favorite

The Role of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Dyslipidemias

By  

Current Pharmaceutical Design, Vol. 15, Iss. 36, 2009-12 ,pp. : 4087-4093

Bentham Science Publishers

Access to resources Recommend Favorite

Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids

By  

Current Pharmaceutical Design, Vol. 20, Iss. 40, 2014-12 ,pp. : 6325-6338

Bentham Science Publishers

Access to resources Recommend Favorite